Hetero inks licensing agreement with Gilead for manufacturing, distribution of remdesivir

Domestic pharma major Hetero on Wednesday said it has entered into a licensing agreement with Gilead Sciences Inc for manufacturing and distribution of remdesivir, a potential therapy for COVID-19

Press Trust of India May 13, 2020 11:40:13 IST
Hetero inks licensing agreement with Gilead for manufacturing, distribution of remdesivir

New Delhi: Domestic pharma major Hetero on Wednesday said it has entered into a licensing agreement with Gilead Sciences Inc for manufacturing and distribution of remdesivir, a potential therapy for COVID-19 .

Under this licensing deal, Hetero -- a leading global producer of anti-retroviral drugs -- will be supplying remdesivir in 127 countries, including India, subject to regulatory approvals in respective countries, the company said in a statement.

Hetero inks licensing agreement with Gilead for manufacturing distribution of remdesivir

Representational image. AP.

Commenting on the development, Hetero Group of Companies Chairman B Partha Saradhi Reddy said the partnership will enable access for this important drug to India and other developing countries at this crucial time.

Click here to follow LIVE updates on coronavirus outbreak

"This agreement also illustrates the significance of global collaboration and the need for coming together to fight the health crises impacting humanity.

"Hetero has developed this product in India and has already been working with the government, Indian Council of Medical Research (ICMR), and Drug Controller General of India (DCGI) for necessary studies and approvals to bring this product to treat COVID-19 patients in India," Reddy added.

Click here to follow LIVE news and updates on stock markets

Remdesivir will be manufactured in the company's formulation facility in Hyderabad, which has been approved by stringent global regulatory authorities such as US Food and Drug Administration (USFDA) and EU, among others, the company said.

Hetero has developed the fully vertically integrated supply chain for this product complementing the 'Make in India' campaign as defined by Prime Minister Narendra Modi, it added.

Updated Date:

also read

Maharashtra logs 3,595 COVID-19 cases, 45 deaths; toll at 1,38,322
India

Maharashtra logs 3,595 COVID-19 cases, 45 deaths; toll at 1,38,322

Maharashtra's COVID-19 recovery rate stands at 97.06 percent, while the fatality rate is 2.12 percent

Maharashtra logs 3,783 COVID-19 cases, 56 more deaths; toll at 1,38,277
India

Maharashtra logs 3,783 COVID-19 cases, 56 more deaths; toll at 1,38,277

Among the eight regions of Maharashtra, the Pune region reported the highest 1,483 new COVID-19 cases, followed by 970 cases in the Mumbai region

Maharashtra adds 2,740 new COVID-19 cases, lowest since 9 Feb; tally tops 65 lakh
India

Maharashtra adds 2,740 new COVID-19 cases, lowest since 9 Feb; tally tops 65 lakh

On 9 February, Maharashtra had reported 2,515 new COVID-19 cases, while 22 deaths were registered on 8 March